StreetAlpha.app
Home › Stocks › COGT

Cogent Biosciences, Inc. (COGT)

Healthcare
$26.71
▼ −3.70%
LAST CLOSE · NOV 20

Cogent Biosciences develops targeted drugs for rare, genetically driven diseases, led by bezuclastinib for systemic mastocytosis and GIST. It last closed at $26.71 on Nov 20, down 3.70% on the day. The next earnings report for COGT is expected around Tue, Feb 16, 2027. For the quarter ended Sep 2026, COGT reported EPS of -$0.59. Over its last 8 reports the stock moved an average of 5.5% the session after earnings. Over the last 12 months COGT insiders bought $0 of stock on the open market and sold $383.9M, according to SEC Form 4 filings.

AI Auto Pilots
Is COGT in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold COGT.

Key Stats

Last 12 months
Results
Net income
−$407.7M
EPS (diluted)
−$2.26
Free cash flow
−$325.8M
Valuation
Market cap
$4.6B
174.0M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$217.5M
At Sep 30
Debt
$223.7M
At Sep 30
Shareholder equity
$516.3M
Shares outstanding
174.0M
At Nov 3
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$72.3M−$72.3MFY2021FY2022: −$140.2M−$140.2MFY2022FY2023: −$192.4M−$192.4MFY2023FY2024: −$255.9M−$255.9MFY2024FY2025: −$328.9M−$328.9MFY2025

From COGT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Feb 16
Estimated date · Time not announced
Reported EPS
-$0.59
Quarter ended Sep 2026
Year ago EPS
-$0.50
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.50Dec '24Mar 2025: -$0.52Mar '25Jun 2025: -$0.53Jun '25Sep 2025: -$0.50Sep '25Dec 2025: -$0.61Dec '25Mar 2026: -$0.53Mar '26Jun 2026: -$0.52Jun '26Sep 2026: -$0.59Sep '26Latest -$0.59
Revenue by quarter
Not enough quarters on file yet.
How COGT moved after its last 8 reports
Average move the session after a report ±5.5%
Nov 5, 2026After the close+7.0%
Aug 10, 2026Time not announced−2.0%
May 5, 2026Time not announced+0.7%
Feb 17, 2026Time not announced+3.0%
Nov 3, 2025Time not announced−4.9%
Jul 10, 2025Time not announced+4.3%
May 6, 2025Time not announced−15.6%
Feb 25, 2025Time not announced−6.3%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on COGTStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on COGT
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on COGT

Technical Analysis

COGT · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 13% below its 20 day and 15% below its 50 day average. It is 31% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 36), near oversold. The nearest support is the 52 week low at $26.36, and the nearest resistance the Pivot at $27.06.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 5.9%/day
Key levels
$43.7352 week high+63.7%
$35.07200 day average+31.3%
$34.43100 day average+28.9%
$31.07Swing high (Oct 12)+16.3%
$30.7150 day average+15.0%
$30.0720 day average+12.6%
$27.49Pivot R1+2.9%
$27.06Pivot+1.3%
$26.71Last close
$26.3652 week low−1.3%
$26.36Swing low (Nov 17)−1.3%
$26.28Pivot S1−1.6%
Indicators
RSI (14)35.65Weak, oversold below 30Neutral
MACD-1.04Below its signal lineBearish
Stochastic13.8Near the bottom of its rangeOversold
ADX (14)20.8Weak trend
Williams %R-95.4Oversold below −80, overbought above −20Oversold
CCI (20)-138.6Oversold below −100, overbought above 100Oversold
Rate of change−15.6%Change over 10 sessionsBearish
ATR (14)$1.56Typical daily range, 5.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for COGT

What happened before

See how COGT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow COGT usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How COGT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2005.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for COGTHow many large options trades hit COGT, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

COGT Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲185 buying vs 149 selling
  • ▲Held by funds +1.5 pts
  • ▼Funds holding -11
  • ▲Superinvestors: 3 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding317328−3.4%
In funds' top 1015150.0%
Held by funds116.0%114.5%+1.5 pts
New / increased51 / 13464 / 138−8.4%
Reduced / sold out89 / 6084 / 46+14.6%
Put/call ratio0.050.15−66.6%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See COGT institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

COGT Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$383.9M7 sales · 6 insiders
2025-12 sold $12.2M2026-01 sold $127.4M2026-03 sold $242.6M2026-08 sold $1.7MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Aug 27Arlene MorrisDirectorSale plan45,510$37.12$1.7M
Mar 31Fairmount Funds Management LLCDirectorSale7,000,000$34.66$242.6M
Jan 22Fairmount Funds Management LLCDirectorSale3,500,000$36.40$127.4M
Dec 26, 2025John Edward RobinsonChief Scientific OfficerSale90,000$38.74$3.5M
Dec 26, 2025Jessica SachsChief Medical OfficerSale82,642$38.70$3.2M
Dec 26, 2025John L. GreenCFOSale77,000$38.68$3.0M
Every insider buy and sale for COGT over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See COGT insider trades →

From SEC Form 4 filings by COGT's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether COGT is in one of them and how their past COGT trades turned out.

COGT in the AI portfolios
Loading…

COGT News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered COGT in an article yet. Here's the latest on the wider market.

COGT in the news

COGT Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Jan 20
Who traded COGT · since 2022
Latest 1 filing
$1K – $15KTraded Dec 12, 2022Filed Jan 20, 2023
PersonTypeAmountTradedFiledDelay
Christopher JacobsR · NYBuy$1K – $15KDec 12, 2022Jan 20, 202339 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Cogent Biosciences

Cogent Biosciences is a biotechnology company based in Waltham, Massachusetts, that develops drugs for diseases caused by specific genetic mutations. Its lead candidate, bezuclastinib, is being studied for systemic mastocytosis, a rare disease in which mast cells build up in the body, and for gastrointestinal stromal tumors, a cancer of the digestive tract. The company is also developing other targeted therapies, including inhibitors aimed at FGFR2/3 and ErbB2 mutations. Its intended patients are people with rare, genetically driven diseases.

Headquarters
Waltham, MA